Table 1.
Characteristics of study population. TACE: Transarterial chemoembolization, HCC: Hepatocellular carcinoma, CRC: Colorectal carcinoma, CCA: Cholangiocarcinoma, OR: objective response.
| Characteristic | Study Cohort |
|---|---|
| TACE patients | 56 |
| Sex (%): | |
| male-female | 78.6–21.4 |
| Age (years, median and range) | 65 (30–89) |
| Hepatic malignancy (%): | |
| HCC | 82.1 |
| Liver metastasis (CRC) | 10.7 |
| Liver metastasis (gastric cancer) | 1.8 |
| Liver metastasis (pancreatic cancer) | 3.6 |
| Liver metastasis (CCA) | 1.8 |
| Size of target lesion (mm, median and range) | 27 (10–129) |
| HCC tumor stage (%): | |
| BCLC A | 34.8 |
| BCLC B | 58.7 |
| BCLC C | 6.5 |
| Child-Pugh Score (HCC only) (%): | |
| No liver cirrhosis | 2.2 |
| CHILD A: | 80.4 |
| 5 points | 56.5 |
| 6 points | 23.9 |
| CHILD B: | 17.4 |
| 7 points | 13 |
| 8 points | 4.4 |
| OR to TACE therapy (%): | |
| Yes–No | 41.5–58.5 |
| Deceased during follow-up (%): | |
| Yes–No | 60.0–40.0 |
| Median overall survival (days/month) | 611/20.4 |